| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Survivors | 15 | 2024 | 724 | 3.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 15 | 2024 | 2850 | 1.880 |
Why?
|
| Neoplasms, Second Primary | 5 | 2021 | 1369 | 1.490 |
Why?
|
| Telomere | 4 | 2016 | 516 | 1.370 |
Why?
|
| Thyroid Neoplasms | 4 | 2021 | 1897 | 1.200 |
Why?
|
| Telomere Shortening | 2 | 2021 | 57 | 1.200 |
Why?
|
| Leukemia, Myeloid, Acute | 14 | 2024 | 7070 | 1.050 |
Why?
|
| Health Equity | 2 | 2024 | 54 | 1.030 |
Why?
|
| Telomerase | 3 | 2020 | 533 | 0.990 |
Why?
|
| Child | 45 | 2024 | 30109 | 0.960 |
Why?
|
| Telomere-Binding Proteins | 3 | 2020 | 84 | 0.900 |
Why?
|
| Mycoses | 2 | 2021 | 386 | 0.880 |
Why?
|
| Dyskeratosis Congenita | 2 | 2013 | 26 | 0.880 |
Why?
|
| Hodgkin Disease | 4 | 2024 | 1459 | 0.850 |
Why?
|
| Neutropenia | 5 | 2023 | 987 | 0.810 |
Why?
|
| Telomere Homeostasis | 2 | 2020 | 70 | 0.800 |
Why?
|
| Frailty | 2 | 2021 | 129 | 0.780 |
Why?
|
| Health Status Disparities | 1 | 2024 | 314 | 0.740 |
Why?
|
| Hyperbilirubinemia | 2 | 2022 | 77 | 0.730 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 200 | 0.720 |
Why?
|
| Neoplasms | 12 | 2024 | 15666 | 0.690 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 255 | 0.670 |
Why?
|
| Wearable Electronic Devices | 1 | 2021 | 111 | 0.660 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 10 | 0.650 |
Why?
|
| Hematologic Neoplasms | 2 | 2021 | 1927 | 0.620 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 130 | 0.620 |
Why?
|
| Long Term Adverse Effects | 1 | 2017 | 23 | 0.600 |
Why?
|
| Down Syndrome | 1 | 2020 | 228 | 0.600 |
Why?
|
| Internet | 2 | 2022 | 725 | 0.580 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 83 | 0.580 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 608 | 0.570 |
Why?
|
| Siblings | 3 | 2019 | 288 | 0.570 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2024 | 5381 | 0.560 |
Why?
|
| Adolescent | 27 | 2024 | 32261 | 0.560 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 204 | 0.560 |
Why?
|
| Infertility | 1 | 2017 | 119 | 0.530 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 462 | 0.510 |
Why?
|
| Radiotherapy | 3 | 2021 | 1852 | 0.500 |
Why?
|
| Genetic Variation | 2 | 2020 | 2041 | 0.500 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2020 | 4316 | 0.490 |
Why?
|
| Cognition Disorders | 1 | 2020 | 787 | 0.480 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 797 | 0.480 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2022 | 6783 | 0.470 |
Why?
|
| Humans | 61 | 2024 | 269838 | 0.460 |
Why?
|
| Minisatellite Repeats | 1 | 2013 | 50 | 0.440 |
Why?
|
| Child, Preschool | 16 | 2024 | 16743 | 0.410 |
Why?
|
| Survivors | 5 | 2024 | 1028 | 0.410 |
Why?
|
| Neurotoxicity Syndromes | 2 | 2024 | 119 | 0.410 |
Why?
|
| Neutrophils | 1 | 2016 | 844 | 0.410 |
Why?
|
| Leukemia, Myeloid | 1 | 2016 | 965 | 0.390 |
Why?
|
| Steroids | 1 | 2013 | 355 | 0.390 |
Why?
|
| Anemia, Aplastic | 1 | 2013 | 230 | 0.390 |
Why?
|
| Fetal Growth Retardation | 1 | 2013 | 205 | 0.390 |
Why?
|
| Health Planning Guidelines | 1 | 2011 | 58 | 0.370 |
Why?
|
| Antifungal Agents | 2 | 2021 | 853 | 0.370 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 2589 | 0.360 |
Why?
|
| Obesity | 3 | 2018 | 2986 | 0.360 |
Why?
|
| Microcephaly | 1 | 2013 | 328 | 0.350 |
Why?
|
| Thrombocytopenia, Neonatal Alloimmune | 1 | 2009 | 2 | 0.350 |
Why?
|
| Risk Factors | 13 | 2024 | 18032 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 16270 | 0.340 |
Why?
|
| Hematology | 1 | 2011 | 101 | 0.340 |
Why?
|
| Wolman Disease | 1 | 2009 | 7 | 0.340 |
Why?
|
| Sterol Esterase | 1 | 2009 | 17 | 0.340 |
Why?
|
| Socioeconomic Factors | 2 | 2024 | 1260 | 0.330 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2009 | 89 | 0.330 |
Why?
|
| Isoantibodies | 1 | 2009 | 122 | 0.330 |
Why?
|
| Cellular Senescence | 1 | 2010 | 386 | 0.310 |
Why?
|
| Cardiovascular Diseases | 2 | 2020 | 2342 | 0.300 |
Why?
|
| Proportional Hazards Models | 5 | 2023 | 5091 | 0.300 |
Why?
|
| Female | 30 | 2024 | 146823 | 0.290 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 14505 | 0.290 |
Why?
|
| Prognosis | 9 | 2024 | 22192 | 0.290 |
Why?
|
| Male | 27 | 2024 | 127192 | 0.280 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2020 | 3066 | 0.280 |
Why?
|
| Young Adult | 11 | 2022 | 22111 | 0.280 |
Why?
|
| Case-Control Studies | 4 | 2021 | 6025 | 0.280 |
Why?
|
| Incidence | 4 | 2020 | 5874 | 0.270 |
Why?
|
| HLA Antigens | 1 | 2009 | 551 | 0.270 |
Why?
|
| Electronics | 2 | 2023 | 56 | 0.260 |
Why?
|
| Methotrexate | 3 | 2024 | 1024 | 0.260 |
Why?
|
| Survivorship | 2 | 2024 | 116 | 0.260 |
Why?
|
| Intellectual Disability | 1 | 2013 | 1039 | 0.260 |
Why?
|
| Longitudinal Studies | 2 | 2021 | 2049 | 0.250 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 1129 | 0.250 |
Why?
|
| Lymphocyte Count | 3 | 2022 | 489 | 0.240 |
Why?
|
| Societies, Medical | 1 | 2011 | 1393 | 0.240 |
Why?
|
| Infant | 10 | 2022 | 13767 | 0.220 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 10581 | 0.210 |
Why?
|
| Body Fluids | 1 | 2023 | 129 | 0.210 |
Why?
|
| Asparaginase | 1 | 2022 | 186 | 0.200 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 101 | 0.200 |
Why?
|
| Central Venous Catheters | 1 | 2022 | 100 | 0.190 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2024 | 1329 | 0.190 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 171 | 0.180 |
Why?
|
| Atrial Function, Left | 1 | 2020 | 29 | 0.180 |
Why?
|
| Retrospective Studies | 12 | 2024 | 39453 | 0.180 |
Why?
|
| Aftercare | 2 | 2022 | 257 | 0.180 |
Why?
|
| Follow-Up Studies | 5 | 2024 | 15183 | 0.180 |
Why?
|
| Thyroid Diseases | 1 | 2020 | 87 | 0.180 |
Why?
|
| Hypersensitivity | 1 | 2022 | 224 | 0.170 |
Why?
|
| Pancreatitis | 1 | 2022 | 279 | 0.170 |
Why?
|
| Echocardiography, Doppler | 1 | 2020 | 183 | 0.170 |
Why?
|
| Poverty | 1 | 2023 | 498 | 0.170 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 205 | 0.170 |
Why?
|
| Adult | 13 | 2024 | 80478 | 0.170 |
Why?
|
| Genome-Wide Association Study | 2 | 2024 | 2075 | 0.170 |
Why?
|
| Catheterization, Central Venous | 1 | 2022 | 364 | 0.160 |
Why?
|
| Catheter-Related Infections | 1 | 2022 | 272 | 0.160 |
Why?
|
| Introns | 1 | 2020 | 433 | 0.160 |
Why?
|
| Anthracyclines | 1 | 2020 | 332 | 0.160 |
Why?
|
| Aging, Premature | 1 | 2018 | 40 | 0.160 |
Why?
|
| Bacterial Infections | 1 | 2022 | 484 | 0.160 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 657 | 0.150 |
Why?
|
| Heart Atria | 1 | 2020 | 367 | 0.150 |
Why?
|
| Fatal Outcome | 2 | 2011 | 834 | 0.150 |
Why?
|
| Cohort Studies | 3 | 2021 | 9448 | 0.150 |
Why?
|
| Stroke Volume | 1 | 2020 | 605 | 0.150 |
Why?
|
| Cerebellar Neoplasms | 1 | 2022 | 469 | 0.150 |
Why?
|
| Renal Insufficiency | 1 | 2020 | 329 | 0.140 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 367 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 547 | 0.140 |
Why?
|
| Longevity | 1 | 2018 | 154 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2020 | 1124 | 0.140 |
Why?
|
| Sleep Wake Disorders | 1 | 2020 | 358 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 731 | 0.140 |
Why?
|
| Medulloblastoma | 1 | 2022 | 571 | 0.140 |
Why?
|
| Infant, Newborn | 5 | 2022 | 8540 | 0.140 |
Why?
|
| Leukocytes | 1 | 2018 | 419 | 0.140 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 448 | 0.140 |
Why?
|
| Sepsis | 1 | 2022 | 668 | 0.140 |
Why?
|
| Ventricular Function, Left | 1 | 2020 | 615 | 0.130 |
Why?
|
| Radiation Pneumonitis | 1 | 2018 | 308 | 0.130 |
Why?
|
| Parent-Child Relations | 1 | 2017 | 263 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2018 | 308 | 0.130 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 1062 | 0.130 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 793 | 0.130 |
Why?
|
| Chronic Disease | 1 | 2020 | 1860 | 0.120 |
Why?
|
| Texas | 3 | 2023 | 6439 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2020 | 742 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 818 | 0.120 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 672 | 0.120 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 3948 | 0.120 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 106 | 0.120 |
Why?
|
| Echocardiography | 1 | 2020 | 1261 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2021 | 2863 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2020 | 754 | 0.120 |
Why?
|
| Alleles | 1 | 2020 | 2391 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 1009 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 1803 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 1117 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 1424 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2018 | 653 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 5917 | 0.110 |
Why?
|
| Remission Induction | 2 | 2016 | 3621 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2020 | 1449 | 0.100 |
Why?
|
| Pedigree | 2 | 2014 | 1879 | 0.100 |
Why?
|
| Inpatients | 1 | 2017 | 699 | 0.100 |
Why?
|
| Sex Distribution | 1 | 2013 | 506 | 0.100 |
Why?
|
| Epilepsy | 1 | 2020 | 933 | 0.100 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2013 | 281 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 713 | 0.100 |
Why?
|
| Acute Disease | 1 | 2016 | 2472 | 0.100 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 1969 | 0.100 |
Why?
|
| Quality of Life | 2 | 2024 | 4716 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 883 | 0.090 |
Why?
|
| Homozygote | 1 | 2013 | 739 | 0.090 |
Why?
|
| Bone Marrow | 1 | 2018 | 2387 | 0.090 |
Why?
|
| Biopsy | 1 | 2018 | 3494 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2019 | 10085 | 0.090 |
Why?
|
| Anxiety | 1 | 2017 | 1245 | 0.090 |
Why?
|
| Philadelphia Chromosome | 1 | 2014 | 827 | 0.090 |
Why?
|
| Algorithms | 1 | 2021 | 3962 | 0.090 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 495 | 0.090 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2009 | 41 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 1051 | 0.080 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2014 | 1127 | 0.080 |
Why?
|
| Translocation, Genetic | 1 | 2014 | 1269 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2018 | 2719 | 0.080 |
Why?
|
| Middle Aged | 5 | 2021 | 89237 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2021 | 7106 | 0.080 |
Why?
|
| Liver Failure | 1 | 2009 | 142 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2492 | 0.070 |
Why?
|
| Mutation | 2 | 2020 | 15578 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6259 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 4894 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 4360 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 5005 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2010 | 16015 | 0.060 |
Why?
|
| Aging | 1 | 2013 | 1569 | 0.060 |
Why?
|
| Neuroblastoma | 1 | 2010 | 695 | 0.060 |
Why?
|
| Selection Bias | 1 | 2024 | 48 | 0.060 |
Why?
|
| NF-kappa B | 1 | 2010 | 1576 | 0.060 |
Why?
|
| Glioma | 1 | 2014 | 1981 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2082 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 3837 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 132 | 0.050 |
Why?
|
| Hypokalemia | 1 | 2022 | 57 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2013 | 9303 | 0.050 |
Why?
|
| Risk | 2 | 2018 | 1959 | 0.050 |
Why?
|
| Demography | 1 | 2022 | 453 | 0.050 |
Why?
|
| Drug Therapy | 1 | 2021 | 204 | 0.050 |
Why?
|
| Creatinine | 1 | 2023 | 552 | 0.050 |
Why?
|
| Systole | 1 | 2020 | 206 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2022 | 449 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2009 | 2302 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2024 | 1217 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2021 | 525 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2022 | 626 | 0.040 |
Why?
|
| Phenotype | 1 | 2010 | 6326 | 0.040 |
Why?
|
| Cardiotoxicity | 1 | 2020 | 161 | 0.040 |
Why?
|
| Biomarkers | 1 | 2010 | 5154 | 0.040 |
Why?
|
| Overweight | 1 | 2022 | 493 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2023 | 787 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2022 | 637 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 627 | 0.040 |
Why?
|
| Recurrence | 2 | 2020 | 4875 | 0.040 |
Why?
|
| Observer Variation | 1 | 2020 | 710 | 0.040 |
Why?
|
| Age Factors | 2 | 2020 | 5475 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 4982 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2023 | 650 | 0.040 |
Why?
|
| Family | 1 | 2021 | 743 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2020 | 623 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1394 | 0.040 |
Why?
|
| Bleomycin | 1 | 2018 | 467 | 0.030 |
Why?
|
| Pregnancy | 1 | 2009 | 7819 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2018 | 314 | 0.030 |
Why?
|
| Parents | 1 | 2023 | 1046 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2014 | 3069 | 0.030 |
Why?
|
| Apoptosis | 1 | 2010 | 7739 | 0.030 |
Why?
|
| SEER Program | 1 | 2019 | 1019 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 1429 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2022 | 3059 | 0.030 |
Why?
|
| Registries | 1 | 2023 | 2281 | 0.030 |
Why?
|
| Kidney | 1 | 2023 | 2199 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 833 | 0.030 |
Why?
|
| Oligodendroglioma | 1 | 2014 | 106 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2022 | 970 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 2728 | 0.030 |
Why?
|
| Hospitalization | 1 | 2023 | 2213 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 2269 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1891 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2020 | 34218 | 0.030 |
Why?
|
| Pediatrics | 1 | 2021 | 1187 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 3391 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2018 | 2280 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 4543 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 6172 | 0.020 |
Why?
|
| Gangliosides | 1 | 2010 | 110 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 3974 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2010 | 468 | 0.020 |
Why?
|
| Exome | 1 | 2014 | 1267 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 2473 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 4452 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3266 | 0.020 |
Why?
|
| Lung | 1 | 2018 | 3221 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 13246 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2010 | 716 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2010 | 1697 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2010 | 1133 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2010 | 2018 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2010 | 3576 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 3628 | 0.010 |
Why?
|
| Aged | 2 | 2023 | 72701 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 5509 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 13287 | 0.010 |
Why?
|
| United States | 1 | 2020 | 16290 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 7745 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 6174 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2010 | 7296 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2010 | 12095 | 0.010 |
Why?
|